The Novo Nordisk Foundation pledged up to DKK 5.5 billion (about €736 million / ~$857 million) to the BioInnovation Institute (BII) to expand operations, increase the number of startups supported from 20 to 40 annually, and scale the institute’s reach across Europe through 2035. The long‑term funding aims to accelerate translation of Danish and regional research into startups and commercial ventures. BII said the investment will help it attract investors and industry partners, broaden scientific coverage, and strengthen Europe’s commercialization pipeline. The foundation framed the move as addressing a gap between scientific excellence and company creation across Europe.